Ford to Move Some Lincoln Production From China to U.S. in 2030 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline 
European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Oil Prices Slide as OPEC, IEA Cut 2026 Demand Forecasts 
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Gold Prices Retreat From Two-Month High as Softer Inflation Eases Fed Rate Hike Bets 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Add as a preferred source on Google
Novartis AG is a Switzerland-based pharmaceutical company that ranks in the top 5 largest pharma brands in the world. It has recently acquired the American biotech firm, Chinook Therapeutics, for $3.5 billion.
Novartis confirmed on Monday, June 12, that it has agreed to a deal that will merge its new subsidiary with Chinook Therapeutics. According to Reuters, the transaction between the companies is expected to be completed by the second half of this year.
Then again, the merger deal is still subject to customary closing conditions. It was also mentioned that this move is completely in accordance with Novartis’ strategy to point its attention to innovative medicines. The buyout will also expand the company’s renal portfolio.
The Swiss pharma further explained that it will acquire the Seattle, Washington-headquartered clinical biotech firm with two high-value, late-stage medicines in development for rare, chronic kidney diseases. Under the contract, shareholders of Chinook will receive $3.2 billion, which is equivalent to $40 per share, in cash. Novartis added that shareholders will also get a contingent value right worth up to $300 million, which will depend on some regulatory achievements.
Meanwhile, Chinook Therapeutics is looking to report data from the last phase of research for its experimental oral drug called Atrasentan, which is used to treat a kidney disease known as IgAN, in the Q4 of 2023. It is currently working on another experimental injectable version of the IgAN treatment called Zigakibart. A late-stage trial for these treatments is set to begin in the third quarter of this year.
“IgA Nephropathy is a devastating disease mostly affecting young adults and potentially leading to dialysis or kidney transplantation,” Novatis’ chief executive officer, Vas Narasimhan, M.D., said in a press release. “We are excited by this unique opportunity to address one of society’s most challenging healthcare issues, with the potential to bring additional much-needed treatment options to patients. We look forward to closing the deal, to a smooth transition for Chinook employees and to welcoming them to Novartis.”
Photo by: Novartis Media Gallery
